Ultrasound Techniques for Detecting Immunotherapy Response in Solid Tumors
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Contrast-enhanced ultrasound (CEUS) for detecting immunotherapy response in solid tumors?
Research shows that contrast-enhanced ultrasound (CEUS) can help predict and evaluate treatment responses in various cancers, such as liver and breast cancer, by providing detailed images of blood flow and tissue changes. This suggests that CEUS might also be effective in assessing how well immunotherapy is working in solid tumors.12345
Is ultrasound safe for detecting immunotherapy response in solid tumors?
How is the ultrasound technique for detecting immunotherapy response in solid tumors different from other treatments?
This treatment is unique because it uses contrast-enhanced ultrasound (CEUS) to predict and evaluate the response to immunotherapy in solid tumors, which is a non-invasive imaging technique that provides real-time information about how well the treatment is working, unlike traditional methods that may require more invasive procedures.123411
What is the purpose of this trial?
Primary objective is to assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by CEUS, can predict initial objective response to therapy, defined by current standard-of-careSecondary objectives are to evaluate if there is an optimal ultrasound imaging modality (CEUS or conventional power Doppler or LEAD ultrasound) or optimal time point to predict initial objective response and to assess the correlation of tumor perfusion parameters with change in overall tumor burden, change in diameter on a per-lesion basis, and with 12-month progression-free survival (PFS).
Research Team
Aya Kamaya, MD
Principal Investigator
Stanford University
Alice C. Fan, MD
Principal Investigator
Stanford University
Jeremy Dahl, Ph.D
Principal Investigator
Stanford University
Eligibility Criteria
This trial is for adults with a confirmed cancer diagnosis who are about to start treatment with immunotherapy drugs like ipilimumab plus nivolumab. They must have at least one solid tumor lesion larger than 1 cm that can be seen on an ultrasound. People allergic to sulfur hexafluoride lipid microsphere or PEG, or those with other serious health issues, cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive standard of care immune checkpoint inhibitor and are followed with ultrasound studies at treatment baseline, 3 weeks, and 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments of tumor burden and progression-free survival
Treatment Details
Interventions
- Contrast-enhanced ultrasound (CEUS)
- Doppler ultrasound
- Long Ensemble Angular-coherence Doppler [LEAD] ultrasound
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Cancer Institute (NCI)
Collaborator